News & Press

GeNeuro: Cash position at December 31, 2020, Business Update and Outlook for 2021

Geneva, Switzerland, January 11, 2021 – 7:30am CET – GeNeuro (Euronext Paris: CH0308403085 - GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced its cash position at December 31, 2020, issued a business update and provided an outlook on its 2021 activities.